AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action, Encourages Investors with Losses to Contact the Firm

Aardvark Therapeutics faces a pending securities class action alleging it misled investors about ARD-101 safety risks and overstated the drug's clinical, regulatory and commercial prospects. The company voluntarily paused its Phase 3 HERO trial on February 27, 2026 following reversible cardiac observations, triggering a stock decline of more than 56%; the FDA subsequently imposed a full clinical hold on ARD-101 on May 14, sending shares down an additional 32.1%. Investors seeking lead-plaintiff status have until October 13, 2026.

Analysis

This is not a new fundamental catalyst: plaintiff-firm notices typically add little incremental valuation information once a clinical hold and safety signal are public. The relevant issue is whether AARD can produce an FDA-acceptable cardiac-risk explanation, including exposure-response data, a revised dosing protocol, and a credible monitoring/mitigation package. Until then, the equity should be valued primarily as cash less a substantial duration-adjusted probability that its lead asset is delayed, dose-limited, or rendered commercially nonviable.

Near term (days to weeks), litigation headlines may worsen retail sentiment and liquidity but are unlikely to drive the stock independently; the October 13 lead-plaintiff deadline is not a business catalyst. Over 1-3 months, the key event is FDA correspondence or company disclosure on the hold's remediation requirements. A narrow hold resolution could create a sharp short-covering rally, whereas any indication that the cardiac effect appears near therapeutic exposure, rather than only at a high-dose margin, materially lowers probability of Phase 3 restart and raises financing/dilution risk.

The non-obvious risk is that even a restart does not restore the original commercial case: added ECG monitoring, restrictive labeling, a lower permissible dose, or longer safety follow-up can reduce enrollment velocity, increase trial cost, and impair eventual payer uptake in a small rare-disease population. Consensus may overreact to the lawsuit itself but underappreciate this post-hold development-time and capital-cost drag. With a single dominant program, there is no meaningful internal diversification to offset that binary exposure.

Key Decisions for Investors

• No new directional position solely on this legal notice; treat it as non-incremental versus the existing clinical-hold thesis. Avoid chasing a gap-down driven only by litigation headlines.
• Maintain a bearish bias on AARD over the next 1-3 months only if borrow is available and position sizing reflects binary FDA-update risk; a short should be covered or hedged if the company discloses a defined remediation path and restart timeline.
• For event-driven exposure, prefer a defined-risk put spread expiring after the next expected FDA/clinical update rather than outright short stock; the thesis is delay/dilution, while the principal adverse scenario is a hold lift producing a large reflex rally.
• Set an alert for cash runway, quarterly operating burn, and any equity-at-the-market filing. If projected cash runway falls below roughly 12 months without a trial restart, dilution becomes the more actionable downside catalyst than litigation.
• Do not use the October 13, 2026 plaintiff deadline as a catalyst. Reassess on FDA feedback, revised protocol details, therapeutic-dose cardiac data, and management guidance on restart timing and incremental trial cost.